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To the Editor: Maturity onset diabetes of the young (MODY)
is an autosomal dominantly inherited form of diabetes that has
been extensively described in white populations, but diag-
nosed with lower frequency in other ethnic groups.
Mutations in the GCK, HNF1A and HNF4A MODY genes
have been reported in a variety of ethnic groups [1–3], but
there are few data on prevalence in non-white ethnic groups.
MODYwas first reported in a UK South Asian (SA) cohort in
a systematic survey of childhood diabetes [4]. A 2006 study
revealed a lower than expected frequency of referrals for
MODY testing in the UK SA population [5]. The frequency
and characteristics of MODY in non-white European popula-
tions is important for the precise diagnosis of young-onset
diabetes.
We undertook a retrospective analysis of UK referrals for
MODY testing to determine if referrals for individuals of SA
origin had increased since that reported in the 2006 study and
to investigate the pick-up rate and clinical features of MODY
mutations in this population.
The UK MODY database, held centrally at the Royal
Devon and Exeter National Health Service (NHS)
Foundation Trust, is populated prospectively from a
standardised request proforma that includes ethnicity.
Proband referrals (>1 year old at diagnosis) from 1996 to
November 2015, in whom sequencing for mutations in the
most common MODY genes (HNF1A, HNF4A, HNF1B or
GCK) was requested, were selected. Only variants classified
as pathogenic or likely pathogenic were included. Assignment
of pathogenicity was based onUK best practice guidelines [6];
including findings from established variant/mutation database
and literature searches, details of familial cosegregation and
identification of clinical features characteristic of the MODY
gene mutation. Additionally, data from in silico prediction
models (SIFT, PolyPhen2, AlignGVGD, Grantham distance
accessed using AlaMut Visual 2.7, Interactive Biosoftware,
Rouen, France) were used, along with details of amino acid
species conservation and predictions of effects on splicing.
Finally, variants in the Exome Aggregation Consortium [7]
and 1000 genomes [8] databases with a minor allele frequency
>0.01, were excluded.
Ethnicity was categorised as white European (WE) or SA
based on UK census classification [9]. The SA group included
people from India, Pakistan and Bangladesh or in whom
ethnic origin was stated to be ‘Asian’ and excluded mixed
ethnicity.
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A total of 4688 proband referrals were identified and
ethnicity was recorded in 4010 cases. White European
referrals accounted for 3472 of 4010 (86.6%). 293 cases
referred were in people of SA ethnicity (7.3%), and 81
referrals (2.0%) were from African or Caribbean
backgrounds (see Table 1).
1180 probands had MODY mutations, with a mutation
pick-up rate of 25.2% (1180/4688). The mutation pick-up rate
was 29.1% (1011/3472) in the WE group and 12.6% (37/293)
in the SA group (p<0.001) (see Table 1). The pick-up rate in
children (<12 years) referred for testing did not differ between
ethnic groups; 32.6% in WE vs 26.7% in SA children,
p=0.356 (data not shown).
Phenotypes of those with and without confirmed MODY
mutations are displayed in Table 2. Generally, SA MODY
patients with GCK mutations were diagnosed earlier than
WE patients (6.5 vs 20 years, p<0.0001); however, when
only considering diagnosis in children under 12 years old,
there was no significant difference in age at diagnosis.
Referrals from both ethnic groups had similar proportions of
a history of parental diabetes and were equally likely to be
non-insulin dependent.
In both SA and WE individuals, the HNF1A / HNF4A
MODYphenotypes were similar across all variables reported
except for HbA1c, which was higher in the SA group (8.6%
[70 mmol/mol] vs 7.2% [55 mmol/mol], p = 0.004; see
Table 2).
SA people in whom noMODYmutations were found were
younger at diagnosis (19 years vs 25 years, p<0.0001) and
had a shorter duration of diabetes, compared with WE indi-
viduals. BMI was similar across both ethnic groups (WE, 25.3
vs SA 25.0 kg/m2, p=0.217). However, SA people were more
likely to have a parent affected with diabetes (83.6% vs
68.2%, p<0.0001) and were more likely not to be treated with
insulin at referral (60.2% vs 50.6%, p = 0.006), when
compared with WE individuals (see Table 2).
This study is the first to explore the characteristics of indi-
viduals of SA ethnicity who have been referred for MODY
testing using data from the largest MODY diagnostic service
in the UK. It demonstrates a lower pick-up rate of MODY
mutations in people of SA ethnicity. In our analysis, SA peo-
ple accounted for markedly more referrals than previously
reported in 2006 (7.3% vs 0.5%) [5]. Whilst this broadly re-
flects the UK population demographics, because of the higher
prevalence of type 2 diabetes in SA people it is suggested that
this is still lower than expected [9]. The detection rate for
MODY mutations was lower in the SA group than in WE
referrals. However, when a mutation was not detected, SA
referrals were more likely to meet the clinical criteria for
MODY thanWE individuals. This may demonstrate a referral
bias favouring SA cases that more stringently meet the clinical
criteria. However, the results also show that these criteria are
not sensitive for the separation of MODY from young-onset
type 2 diabetes in this population. For example, SA people
without mutations had higher BMIs than those with confirmed
MODY mutations, suggesting that the low MODY detection
rate in this group may have resulted from a higher prevalence
of young-onset, familial diabetes.
When analysing the SA group as a whole, the best predic-
tors differentiating those with MODY (mutations in all genes)
from those without a mutation, were a lower BMI and age at
onset; BMI was lower in the SA group withMODYmutations
than those without mutations (MODY, 21.4 kg/m2 and no
MODY, 25.0 kg/m2, p=0.001, data not shown), but BMI
was generally higher and non-significantly different in the
no mutation group when compared with WE people (25.0 vs
25.3 kg/m2, respectively). The lower BMI and age at diagno-
sis in SA referrals was primarily observed in the GCK muta-
tion group and not seen in the HNF1A / HNF4A mutation or
‘no mutation’ groups. It is likely that these findings reflect a
lower referral rate in adults and children over 12 years old
since the mutation pick-up rate in both ethnic groups was
similar in children under 12 years.
There is limited evidence to support that SA indi-
viduals have a lower prevalence of MODY, with only
one previous study suggesting fewer GCK mutations
Table 1 Breakdown of proband
referrals for MODY genetic test-
ing and MODYpick-up rate by
ethnic group
Ethnic group n % MODY mutation (n) Pick-up rate (%)
All groups 4688 1180 25.2
Individuals with known ethnicity 4010 1083 27.0
White 3472 86.6 1011 29.1
South Asian 293 7.3 37 12.6***
African-Caribbean 81 2 8 9.9
Middle Eastern 47 1.2 5 10.6
South East Asian 21 0.5 6 28.6
Mixed/other 96 2.4 16 16.7
All non-white ethnic groups 538 13.4 72 13.4
Statistical analysis was carried out using a χ2 test on the two largest ethnic groups, white and South Asian
***p< 0.001 vs white individuals
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occurred in Indian children [10]; however, this study
may have been underpowered since the estimated
minimum prevalence of MODY (in a predominantly
white population) has recently been demonstrated to
be 1 in 1000 cases [11]. Thus, it is more likely that
the lower mutation pick-up rate in SA individuals
compared to WE individuals observed in our study
reflects higher prevalence of younger-onset type 2
diabetes, which is supported by our analysis demon-
strating similar mutation pick-up rates between ethnic
groups in pre-pubertal children.
Our data highlight the need to consider the optimum
method for identifying cases of MODY in people of
non-white European ethnicity. Approaches such as the
MODY probability calculator [12] need to be validated
in non-white populations as our data suggest that
MODY cases may be more sensitively identified using
lower cut-offs for age at diagnosis and BMI.
Referrals for MODY testing in the SA population have
increased considerably but may still be under-representative
of the general UK population. Meanwhile, despite meeting
referral criteria more stringently, the lower MODY mutation
pick-up rate for SA individuals suggests that these criteria are
not sensitive for separatingMODY from younger-onset type 2
diabetes in the UK SA population.
Further work is required in unselected cohorts, to develop
ethnic-specific criteria that facilitate the identification of
MODY from type 2 diabetes in SA people with young-onset
diabetes.
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